|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,051,000.00 KRW | -1.78% |
|
+5.10% | +10.75% |
| 07-18 | South Korean shares fall on profit taking, but end week higher | RE |
| 07-18 | Samsung Bioepis Signs Deal with Harrow for US Ophthalmology Biosimilar Commercialization | MT |
| Capitalization | 74,804B 53.78B 46.3B 43.09B 40.17B 73.83B 4,632B 82.58B 520B 196B 2,171B 202B 198B 8,022B | P/E ratio 2025 * |
54.3x | P/E ratio 2026 * | 46.6x |
|---|---|---|---|---|---|
| Enterprise value | 74.04B 53.23M 45.83M 42.65M 39.76M 73.08M 4.58B 81.74M 515M 194M 2.15B 200M 196M 7.94B | EV / Sales 2025 * |
13.1x | EV / Sales 2026 * | 11.1x |
| Free-Float |
25.44% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
More news
| 1 day | -1.78% | ||
| 1 week | +5.10% | ||
| Current month | +5.95% | ||
| 1 month | +5.10% | ||
| 3 months | +5.10% | ||
| 6 months | +5.10% | ||
| Current year | +10.75% |
| 1 week | 1,000,000 |  | 1,080,000 |
| 1 month | 990,000 | | 1,080,000 |
| Current year | 924,000 | | 1,080,000 |
| 1 year | 826,000 | | 1,080,000 |
| 3 years | 668,000 | | 1,080,000 |
| 5 years | 624,000 | | 1,080,000 |
| 10 years | 125,500 | | 1,080,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 63 | 08/12/2020 |
Dong-Joong Kim
DFI | Director of Finance/CFO | 60 | 31/12/2013 |
Yong-Ho An
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Dong-Joong Kim
BRD | Director/Board Member | 60 | 31/12/2013 |
Geun-Nyeong Heo
BRD | Director/Board Member | 69 | 21/03/2019 |
John Chongbo Rim
BRD | Director/Board Member | 63 | - |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.43% | 17 M€ | +10.48% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.78% | +5.10% | +23.65% | +29.75% | 53.86B | ||
| +3.62% | +6.83% | -17.27% | -13.24% | 81.33B | ||
| -1.36% | -4.44% | -48.99% | -8.93% | 57.33B | ||
| +0.49% | +2.28% | +27.49% | +106.34% | 38.73B | ||
| -0.06% | +10.55% | +118.53% | +146.33% | 19.4B | ||
| +0.31% | +11.62% | +86.31% | +820.19% | 18.86B | ||
| -2.88% | -6.87% | -44.79% | -43.25% | 18.31B | ||
| -0.04% | -.--% | +76.16% | +135.78% | 14.02B | ||
| -1.57% | -1.06% | +3.02% | -16.59% | 13.14B | ||
| -2.92% | -7.07% | -74.20% | -81.30% | 12.09B | ||
| Average | -0.62% | +1.32% | +14.99% | +107.51% | 32.71B | |
| Weighted average by Cap. | +0.11% | +1.96% | +4.41% | +68.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 5,673B 4.08B 3.51B 3.27B 3.05B 5.6B 351B 6.26B 39.43B 14.89B 165B 15.3B 14.98B 608B | 6,562B 4.72B 4.06B 3.78B 3.52B 6.48B 406B 7.24B 45.61B 17.22B 190B 17.7B 17.33B 704B |
| Net income | 1,379B 991M 854M 794M 740M 1.36B 85.39B 1.52B 9.58B 3.62B 40.02B 3.72B 3.64B 148B | 1,606B 1.15B 994M 925M 862M 1.58B 99.44B 1.77B 11.16B 4.21B 46.6B 4.33B 4.24B 172B |
| Net Debt | -764B -549M -473M -440M -410M -754M -47.32B -844M -5.31B -2.01B -22.18B -2.06B -2.02B -81.95B | -1,909B -1.37B -1.18B -1.1B -1.03B -1.88B -118B -2.11B -13.27B -5.01B -55.4B -5.15B -5.04B -205B |
More financial data
* Estimated data
Employees
4,770
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/07/25 | 1,051,000.00 ₩ | -1.78% | 76,032 |
| 17/07/25 | 1,070,000.00 ₩ | +3.58% | 106,309 |
| 16/07/25 | 1,033,000.00 ₩ | +0.19% | 47,965 |
| 15/07/25 | 1,031,000.00 ₩ | -1.06% | 76,808 |
| 14/07/25 | 1,042,000.00 ₩ | -1.42% | 55,795 |
End-of-day quote Korea S.E., July 17, 2025
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
1,051,000.00KRW
Average target price
1,318,038.46KRW
Spread / Average Target
+25.41%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- A207940 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition